Chapter

Selection of patients for endocrine therapies

W. Fraser Symmans and Lajos Pusztai

in Endocrine Therapies in Breast Cancer

Published on behalf of Oxford University Press

ISBN: 9780199218141
Published online May 2011 | e-ISBN: 9780199606993 | DOI: http://dx.doi.org/10.1093/med/9780199218141.003.0001

Series: Oxford Oncology Library

Selection of patients for endocrine therapies

Show Summary Details

Preview

• Diagnostic tests that target the presence of oestrogen receptor (ER) expression or activity are used to deter-mine a patient’s eligibility for endocrine therapies. • It is appropriate to test in situ, invasive, or recurrent breast cancer for ER expression or activity to select patients for preventative, adjuvant, or palliative endocrine therapies. • Current tests accurately exclude eligibility for endocrine therapies, but have only modest positive predictive value. • Novel multiplex molecular assays have demonstrated considerable potential to further refine the selection of patients for endocrine therapies. • Future tests could discriminate between different clinical treatment options.

Chapter.  4004 words.  Illustrated.

Subjects: Clinical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.